Oral oncology最新文献

英文中文

Mandibular canal invasion as a T4a criterion: a step forward with important caveats 下颌管侵犯作为T4a标准：向前迈出了重要的一步

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-01-16 DOI: 10.1016/j.oraloncology.2026.107856

Suhani Ghai

引用次数: 0

Methodological and clinical considerations for a novel nomogram predicting central lymph node metastasis in papillary thyroid microcarcinoma 一种预测甲状腺乳头状微癌中央淋巴结转移的新型nomogram方法学和临床研究

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-01-16 DOI: 10.1016/j.oraloncology.2026.107855

Weiqun Wang, Yaling Lou

引用次数: 0

Advancing methodological rigor in exercise oncology trials for head and neck cancer 提高头颈癌运动肿瘤学试验方法的严谨性

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-01-16 DOI: 10.1016/j.oraloncology.2026.107857

Congcong Cheng, Juanjuan Zhang

引用次数: 0

From risk factors to clinical Decisions: Methodological Considerations in Predicting occult metastasis in papillary thyroid carcinoma 从危险因素到临床决策：预测甲状腺乳头状癌隐匿转移的方法学考虑

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-01-15 DOI: 10.1016/j.oraloncology.2026.107854

Weiqun Wang, Yaling Lou

引用次数: 0

Perioperative immunotherapy for head and neck cancer: from early successes to clinical challenges in relapsed and/or metastatic disease 头颈癌围手术期免疫治疗：从早期成功到复发和/或转移性疾病的临床挑战

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-01-15 DOI: 10.1016/j.oraloncology.2026.107853

Francesca Carosi , Sara Demurtas , Antonio Ciarfella , Ester Orlandi , Laura D. Locati

引用次数: 0

Incorporation of grade into stage in oral cavity squamous cell carcinoma: A novel staging schema 将口腔鳞状细胞癌的分级纳入分期：一种新的分期模式

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-01-13 DOI: 10.1016/j.oraloncology.2025.107847

Allen S. Ho , Michael Luu , Daniel Manzoor , Horacio Maluf , Cedric Bailey , Bonnie Balzer , Evan S. Walgama , Julie K. Jang , Kevin C. Scher , Justin T. Moyers , Jon Mallen-St. Clair , Joel B. Epstein , Zachary S. Zumsteg

Background

While numerous cancer staging systems have incorporated grade into stage, the impact of grade on oral cavity carcinoma (OCC) prognosis has been conflicting. We investigated grade as a prognostic determinant in OCC staging.

Methods

Multivariable Cox regression models of OCC patients identified via U.S. cancer registry data were constructed to determine associations between grade (G1 = low-grade, G2 = intermediate-grade, G3 = high-grade) and overall survival (OS). Recursive partitioning analysis (RPA) was used to derive staging schema.

Results

Overall, 46,789 OCC cases were identified across 1,222 institutions. On univariate analysis, higher grade was associated with worse 5-yr OS (G1: 73% [95% CI 72–74%], G2: 61% [95 CI 60–61%], G3: 49% [95% CI 48–51%] (p < 0.001). On multivariable analysis adjusting for other prognostic factors, these survival differences persisted. Compared to G1 tumors, both G2 (HR 1.25 [95% CI 1.19–1.30], p < 0.001) and G3 (HR 1.52 [95% CI 1.45–1.61], p < 0.001) tumors were associated with significantly worse OS. Similar results were seen when utilizing propensity score matching. RPA generated subgroups that mirrored AJCC8E, but with G3 cases performing worse for a given stage. A proposed TNM + G staging schema was created with AJCC8E G3 cases upstaged by one category. Overall, 11.5% (4,745/36,623) cases were upstaged. TNM + G performed better than AJCC8E by c-index (0.673 vs. 0.671) and Brier score (0.174 vs. 0.175).

Conclusion

Large-scale analysis supports grade as an influential predictive determinant in OCC outcomes, with hazard on par with conventional staging factors. Incorporation of grade into stage strengthens existing AJCC OCC schema and pragmatically improves its ability to convey prognosis.

虽然许多癌症分期系统都将分级纳入分期，但分级对口腔癌（OCC）预后的影响一直存在矛盾。我们研究了分级作为OCC分期的预后决定因素。方法构建通过美国癌症登记数据确定的OCC患者的多变量Cox回归模型，以确定分级（G1 =低分级，G2 =中分级，G3 =高分级）与总生存期（OS）之间的关系。采用递归分区分析（RPA）导出分级模式。结果在1222家机构共发现46789例OCC病例。在单因素分析中，较高的分级与较差的5年OS相关(G1: 73% [95% CI 72-74%], G2: 61% [95 CI 60-61%], G3: 49% [95% CI 48-51%] （p < 0.001）。在调整其他预后因素的多变量分析中，这些生存差异仍然存在。与G1肿瘤相比，G2肿瘤（HR 1.25 [95% CI 1.19-1.30], p < 0.001）和G3肿瘤（HR 1.52 [95% CI 1.45-1.61], p < 0.001）的OS均显著恶化。当使用倾向得分匹配时，可以看到类似的结果。RPA生成的子组反映了AJCC8E，但G3病例在给定阶段的表现更差。提出了一个TNM + G分期模式，其中AJCC8E G3病例被一个类别抢了上风。总体而言，11.5%（4745 / 36623）病例被抢镜。TNM + G的c指数（0.673比0.671）和Brier评分（0.174比0.175）优于AJCC8E。结论：大规模分析支持分级是OCC预后的重要预测因素，其危险性与传统分期因素相当。将分级纳入分期强化了现有的AJCC OCC图式，切实提高了其传达预后的能力。

{"title":"Incorporation of grade into stage in oral cavity squamous cell carcinoma: A novel staging schema","authors":"Allen S. Ho , Michael Luu , Daniel Manzoor , Horacio Maluf , Cedric Bailey , Bonnie Balzer , Evan S. Walgama , Julie K. Jang , Kevin C. Scher , Justin T. Moyers , Jon Mallen-St. Clair , Joel B. Epstein , Zachary S. Zumsteg","doi":"10.1016/j.oraloncology.2025.107847","DOIUrl":"10.1016/j.oraloncology.2025.107847","url":null,"abstract":"<div><h3>Background</h3><div>While numerous cancer staging systems have incorporated grade into stage, the impact of grade on oral cavity carcinoma (OCC) prognosis has been conflicting. We investigated grade as a prognostic determinant in OCC staging.</div></div><div><h3>Methods</h3><div>Multivariable Cox regression models of OCC patients identified via U.S. cancer registry data were constructed to determine associations between grade (G1 = low-grade, G2 = intermediate-grade, G3 = high-grade) and overall survival (OS). Recursive partitioning analysis (RPA) was used to derive staging schema.</div></div><div><h3>Results</h3><div>Overall, 46,789 OCC cases were identified across 1,222 institutions. On univariate analysis, higher grade was associated with worse 5-yr OS (G1: 73% [95% CI 72–74%], G2: 61% [95 CI 60–61%], G3: 49% [95% CI 48–51%] (p < 0.001). On multivariable analysis adjusting for other prognostic factors, these survival differences persisted. Compared to G1 tumors, both G2 (HR 1.25 [95% CI 1.19–1.30], p < 0.001) and G3 (HR 1.52 [95% CI 1.45–1.61], p < 0.001) tumors were associated with significantly worse OS. Similar results were seen when utilizing propensity score matching. RPA generated subgroups that mirrored AJCC8E, but with G3 cases performing worse for a given stage. A proposed TNM + G staging schema was created with AJCC8E G3 cases upstaged by one category. Overall, 11.5% (4,745/36,623) cases were upstaged. TNM + G performed better than AJCC8E by c-index (0.673 vs. 0.671) and Brier score (0.174 vs. 0.175).</div></div><div><h3>Conclusion</h3><div>Large-scale analysis supports grade as an influential predictive determinant in OCC outcomes, with hazard on par with conventional staging factors. Incorporation of grade into stage strengthens existing AJCC OCC schema and pragmatically improves its ability to convey prognosis.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107847"},"PeriodicalIF":3.9,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145978460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study PD-1抑制治疗复发/转移性头颈部鳞状细胞癌中p16和免疫细胞浸润的预后意义：一项全国DAHANCA队列研究

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-01-12 DOI: 10.1016/j.oraloncology.2026.107849

Sebastian Søby , Danny Mortensen , Anita Gothelf , Niels Gyldenkerne , Christian Maare , Camilla K Lonkvist , Maria Andersen , Rasmus Kjeldsen , Kasper Toustrup , Trine Tramm , Jesper Grau Eriksen

PD-1 inhibition has become an established treatment option for recurrent/metastatic head and neck squamous cell carcinoma (rmHNSCC). However, there is a clear need for improved prognostic tools.

This study aimed to identify immune-related tissue biomarkers associated with overall survival (OS) or progression-free survival (PFS) in patients treated with PD-1 inhibition.

This national real-world phase IV multicenter retrospective cohort study included Danish patients treated between 2017 and 2023. Pre-treatment biopsies were collected for immunohistochemical analyses. All patients were PD-L1 positive with histologically confirmed rmHNSCC treated with pembrolizumab or nivolumab monotherapy.

Biomarker expression was assessed for CD4, CD8, FOXP3, CD20, CD66b, CD68, STING, cGAS, and tumor-infiltrating lymphocytes (TILs), using the median expression as the cut-off value.

Formalin-fixed, paraffin-embedded tumor tissue was obtained from 263 eligible patients. Concurrent above median levels of FOXP3 and CD68 were associated with a lower risk of progression (HR_PFS: 0.47 [95 % CI: 0.33–0.67]). This interaction appeared to be driven by p16+ oropharyngeal cancers (OPC), where patients with concurrent above median levels of FOXP3 and CD68 showed a median 2-year PFS of 68 % [95 % CI: 42–86] in contrast to those with one or none of the two markers above the median level with a 2-year PFS of 3 % [95 % CI: 0–12] (p < 0.001).

In this real-world cohort, a subgroup with a promising prognosis was identified. This subgroup was characterized by p16+ OPC along with concurrent above median levels of FOXP3 and CD68. PD-L1 alone showed no significant association with outcomes.

PD-1抑制已成为复发/转移性头颈部鳞状细胞癌（rmHNSCC）的既定治疗选择。然而，显然需要改进预后工具。该研究旨在鉴定与PD-1抑制治疗患者总生存期（OS）或无进展生存期（PFS）相关的免疫相关组织生物标志物。这项全国性的现实世界IV期多中心回顾性队列研究纳入了2017年至2023年接受治疗的丹麦患者。收集治疗前活检进行免疫组织化学分析。所有患者均为PD-L1阳性，组织学证实rmHNSCC接受派姆单抗或纳武单抗单药治疗。评估CD4、CD8、FOXP3、CD20、CD66b、CD68、STING、cGAS和肿瘤浸润淋巴细胞（TILs）的生物标志物表达，以中位数表达作为临界值。263例符合条件的患者采用福尔马林固定、石蜡包埋的肿瘤组织。FOXP3和CD68同时高于中位水平与较低的进展风险相关（HRPFS: 0.47 [95% CI: 0.33-0.67]）。这种相互作用似乎是由p16+口咽癌（OPC）驱动的，其中FOXP3和CD68同时高于中位水平的患者的2年PFS中位数为68% [95% CI: 42-86]，而两种标志物中有一种或无一种高于中位水平的患者的2年PFS中位数为3% [95% CI: 0-12] (p

{"title":"Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study","authors":"Sebastian Søby , Danny Mortensen , Anita Gothelf , Niels Gyldenkerne , Christian Maare , Camilla K Lonkvist , Maria Andersen , Rasmus Kjeldsen , Kasper Toustrup , Trine Tramm , Jesper Grau Eriksen","doi":"10.1016/j.oraloncology.2026.107849","DOIUrl":"10.1016/j.oraloncology.2026.107849","url":null,"abstract":"<div><div>PD-1 inhibition has become an established treatment option for recurrent/metastatic head and neck squamous cell carcinoma (rmHNSCC). However, there is a clear need for improved prognostic tools.</div><div>This study aimed to identify immune-related tissue biomarkers associated with overall survival (OS) or progression-free survival (PFS) in patients treated with PD-1 inhibition.</div><div>This national real-world phase IV multicenter retrospective cohort study included Danish patients treated between 2017 and 2023. Pre-treatment biopsies were collected for immunohistochemical analyses. All patients were PD-L1 positive with histologically confirmed rmHNSCC treated with pembrolizumab or nivolumab monotherapy.</div><div>Biomarker expression was assessed for CD4, CD8, FOXP3, CD20, CD66b, CD68, STING, cGAS, and tumor-infiltrating lymphocytes (TILs), using the median expression as the cut-off value.</div><div>Formalin-fixed, paraffin-embedded tumor tissue was obtained from 263 eligible patients. Concurrent above median levels of FOXP3 and CD68 were associated with a lower risk of progression (HR<sub>PFS</sub>: 0.47 [95 % CI: 0.33–0.67]). This interaction appeared to be driven by p16+ oropharyngeal cancers (OPC), where patients with concurrent above median levels of FOXP3 and CD68 showed a median 2-year PFS of 68 % [95 % CI: 42–86] in contrast to those with one or none of the two markers above the median level with a 2-year PFS of 3 % [95 % CI: 0–12] (p < 0.001).</div><div>In this real-world cohort, a subgroup with a promising prognosis was identified. This subgroup was characterized by p16+ OPC along with concurrent above median levels of FOXP3 and CD68. PD-L1 alone showed no significant association with outcomes.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107849"},"PeriodicalIF":3.9,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145966683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study nivolumab治疗晚期头颈癌的现实世界有效性和医疗保健利用：一项基于现实世界人群的描述性研究

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-01-08 DOI: 10.1016/j.oraloncology.2026.107851

Wei Fang Dai , Lena Nguyen , Ning Liu , Kelvin KW Chan

Introduction

Nivolumab was the first immunotherapy to have shown efficacy in platinum-resistant recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHNC) in the CheckMate-141 trial. We conducted a population-based retrospective study to examine the survival outcomes and resource utilization of patients with R/M SCCHNC who were treated with nivolumab.

Method

Patients with R/M SCCHNC were included in the study if they received nivolumab between January 17th 2018 to August 31st 2022 in Ontario, Canada. The primary outcomes, including overall survival (OS) and time-to-treatment discontinuation (TTD), were assessed using Kaplan-Meier. Cox proportional hazard model was used to explore the association between baseline patient characteristics and all-cause death. The incidence of healthcare utilization was estimated using the cumulative incidence function, taking death as a competing event.

Results

A total of 498 R/M SCCHNC patients received nivolumab (Mean age 62.9, 78.7 % male). The median OS was 6.0 months (95 % CI: 5.0–7.3) and median time-to-treatment discontinuation was 2.6 months (95 % CI: 2.3–3.0). There is no significant OS difference between older patients (age > 75 years old) and younger patients (p-value 0.73). At 1-year post-nivolumab initiation, the cumulative incidence of emergency department visits is 50.6 % (95 % CI: 46.1–55.0 %) and direct hospitalization is 22.7 % (19.0–26.6 %).

Conclusion

In this real-world study, the survival outcomes of nivolumab were similar to those observed in CheckMate-141 trial. We demonstrated that there is no survival difference between older and younger patients. Furthermore, more than half of patients exaperienced an hospital encounter with the healthcare system, suggesting significant healthcare resource utilization.

在CheckMate-141试验中，nivolumab是首个显示对铂耐药复发和/或转移性头颈部鳞状细胞癌（R/M SCCHNC）有效的免疫疗法。我们进行了一项基于人群的回顾性研究，以检查接受纳武单抗治疗的R/M SCCHNC患者的生存结局和资源利用情况。方法将2018年1月17日至2022年8月31日在加拿大安大略省接受纳武单抗治疗的R/M SCCHNC患者纳入研究。主要结局包括总生存期（OS）和治疗停止时间（TTD），采用Kaplan-Meier法进行评估。采用Cox比例风险模型探讨患者基线特征与全因死亡之间的关系。以死亡为竞争事件，采用累积发生率函数估计医疗保健利用的发生率。结果共498例R/M SCCHNC患者接受尼武单抗治疗，平均年龄62.9岁，男性78.7%。中位OS为6.0个月（95% CI: 5.0-7.3），中位停药时间为2.6个月（95% CI: 2.3-3.0）。老年患者（75岁）与年轻患者的OS无显著差异（p值0.73）。在纳武单抗开始治疗1年后，急诊科就诊的累计发生率为50.6% (95% CI: 46.1 - 55.0%)，直接住院的累计发生率为22.7%（19.0 - 26.6%）。在这项现实世界的研究中，nivolumab的生存结果与CheckMate-141试验中观察到的相似。我们证明了老年和年轻患者之间没有生存差异。此外，超过一半的患者与医疗保健系统有过医院接触，这表明医疗保健资源的利用率很高。

{"title":"Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study","authors":"Wei Fang Dai , Lena Nguyen , Ning Liu , Kelvin KW Chan","doi":"10.1016/j.oraloncology.2026.107851","DOIUrl":"10.1016/j.oraloncology.2026.107851","url":null,"abstract":"<div><h3>Introduction</h3><div>Nivolumab was the first immunotherapy to have shown efficacy in platinum-resistant recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHNC) in the CheckMate-141 trial. We conducted a population-based retrospective study to examine the survival outcomes and resource utilization of patients with R/M SCCHNC who were treated with nivolumab.</div></div><div><h3>Method</h3><div>Patients with R/M SCCHNC were included in the study if they received nivolumab between January 17th 2018 to August 31st 2022 in Ontario, Canada. The primary outcomes, including overall survival (OS) and time-to-treatment discontinuation (TTD), were assessed using Kaplan-Meier. Cox proportional hazard model was used to explore the association between baseline patient characteristics and all-cause death. The incidence of healthcare utilization was estimated using the cumulative incidence function, taking death as a competing event.</div></div><div><h3>Results</h3><div>A total of 498 R/M SCCHNC patients received nivolumab (Mean age 62.9, 78.7 % male). The median OS was 6.0 months (95 % CI: 5.0–7.3) and median time-to-treatment discontinuation was 2.6 months (95 % CI: 2.3–3.0). There is no significant OS difference between older patients (age > 75 years old) and younger patients (p-value 0.73). At 1-year post-nivolumab initiation, the cumulative incidence of emergency department visits is 50.6 % (95 % CI: 46.1–55.0 %) and direct hospitalization is 22.7 % (19.0–26.6 %).</div></div><div><h3>Conclusion</h3><div>In this real-world study, the survival outcomes of nivolumab were similar to those observed in CheckMate-141 trial. We demonstrated that there is no survival difference between older and younger patients. Furthermore, more than half of patients exaperienced an hospital encounter with the healthcare system, suggesting significant healthcare resource utilization.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107851"},"PeriodicalIF":3.9,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145927690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting occult lymph node metastasis in level II using preoperative factors 利用术前因素预测II级隐匿淋巴结转移。

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-01-07 DOI: 10.1016/j.oraloncology.2026.107850

Chengwei Xing , Siyuan Xu , Ruiying Liu , Qiuju Wang , Jie Liu

Background

Super-selective neck dissection which declining level II and V for better neck function preservation remains controversial in the treatment of papillary thyroid carcinoma (PTC). This study aims to explore association between occult lymph node metastasis (OLNM) in level II and preoperative clinical characteristics.

Methods

This retrospective study reviewed unilateral cN1b PTC patients who underwent surgery (2000–2017), with clinical lateral neck metastasis limiting in level III and IV. The OLNM in level II was assessed with preoperative clinical characteristics using logistic regression model; its association with pathological nodes distribution was examined with restricted cubic spline; the prognosis value of level II OLNM was evaluated using Kaplan–Meier method and Cox regression model.

Results

A total of 640 patients (mean [SD] age, 41[11.3] years; 440[68.8 %] female individuals; 307[48.0 %] with OLNM in level II) were analyzed. Primary tumor size (>1.5 cm, OR, 1.625[1.174–2.252]; P = 0.003) and clinical positive lymph nodes (multiple, OR, 4.241 [2.283–8.506]; P < 0.001) are associated with elevated risk of level II OLNM. A non-linear relationship was found between level II OLNM and metastatic lymph nodes number in levels III and IV. No significant difference in all-site recurrence-free survival (RFS) or regional RFS was found between patients with or without level II OLNM, even after adjusting other potential risk factors.

Conclusion

The primary tumor size and metastatic burden in adjacent cervical compartments are associated with risk of level II OLNM, super-selective neck dissection could be considered in patients with small primary tumor cancer and low metastatic burden.

背景：在甲状腺乳头状癌（PTC）的治疗中，为了更好地保留颈部功能而降低II级和V级的超选择性颈部清扫术仍然存在争议。本研究旨在探讨II级隐匿淋巴结转移（OLNM）与术前临床特征的关系。方法：本回顾性研究回顾了2000-2017年接受手术的单侧cN1b PTC患者，临床侧颈转移仅限于III级和IV级。II级的OLNM采用logistic回归模型评估术前临床特征；用受限三次样条分析其与病理淋巴结分布的关系；采用Kaplan-Meier法和Cox回归模型评价II级OLNM的预后价值。结果：共分析640例患者（平均[SD]年龄41[11.3]岁，女性440例[68.8%]，II级OLNM 307例[48.0%]）。原发肿瘤大小（>1.5 cm， OR, 1.625[1.174-2.252]; P = 0.003）和临床阳性淋巴结（多个，OR, 4.241 [2.283-8.506]）； P结论：相邻颈间室原发肿瘤大小和转移负担与II级OLNM发生风险相关，原发肿瘤小、转移负担低的患者可考虑超选择性颈部清扫。

{"title":"Predicting occult lymph node metastasis in level II using preoperative factors","authors":"Chengwei Xing , Siyuan Xu , Ruiying Liu , Qiuju Wang , Jie Liu","doi":"10.1016/j.oraloncology.2026.107850","DOIUrl":"10.1016/j.oraloncology.2026.107850","url":null,"abstract":"<div><h3>Background</h3><div>Super-selective neck dissection which declining level II and V for better neck function preservation remains controversial in the treatment of papillary thyroid carcinoma (PTC). This study aims to explore association between occult lymph node metastasis (OLNM) in level II and preoperative clinical characteristics.</div></div><div><h3>Methods</h3><div>This retrospective study reviewed unilateral cN1b PTC patients who underwent surgery (2000–2017), with clinical lateral neck metastasis limiting in level III and IV. The OLNM in level II was assessed with preoperative clinical characteristics using logistic regression model; its association with pathological nodes distribution was examined with restricted cubic spline; the prognosis value of level II OLNM was evaluated using Kaplan–Meier method and Cox regression model.</div></div><div><h3>Results</h3><div>A total of 640 patients (mean [SD] age, 41[11.3] years; 440[68.8 %] female individuals; 307[48.0 %] with OLNM in level II) were analyzed. Primary tumor size (>1.5 cm, OR, 1.625[1.174–2.252]; P = 0.003) and clinical positive lymph nodes (multiple, OR, 4.241 [2.283–8.506]; P < 0.001) are associated with elevated risk of level II OLNM. A non-linear relationship was found between level II OLNM and metastatic lymph nodes number in levels III and IV. No significant difference in all-site recurrence-free survival (RFS) or regional RFS was found between patients with or without level II OLNM, even after adjusting other potential risk factors.</div></div><div><h3>Conclusion</h3><div>The primary tumor size and metastatic burden in adjacent cervical compartments are associated with risk of level II OLNM, super-selective neck dissection could be considered in patients with small primary tumor cancer and low metastatic burden.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107850"},"PeriodicalIF":3.9,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Establishment of novel stable human sinonasal NUT carcinoma cell lines 稳定的新型人鼻窦NUT癌细胞系的建立。

IF 3.9 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology

Pub Date : 2026-01-03 DOI: 10.1016/j.oraloncology.2025.107828

Yoko Takahashi , Diana Bell , Arnoldo Corona , Shirely Y Su , Renata Ferrarotto , Brandon Gunn , Franco DeMonte , Shaan Raza , Ehab Y Hanna

Purpose

NUT carcinoma is a rare and aggressive malignancy defined by NUTM1 gene rearrangements, with no standard treatment approaches and limited preclinical models, especially for tumors arising in the sinonasal tract. We aimed to establish and characterize novel, stable sinonasal NUT carcinoma cell lines derived from the primary disease site to contribute to therapeutic development.

Experimental design

Tumor specimens from a sinonasal NUT carcinoma patient were cultured to establish two cell lines, MDA-NUT87 and MDA-NUT88. Cytogenetic analysis, immunohistochemistry, RT-PCR, and Sanger sequencing confirmed the presence of the BRD4::NUTM1 fusion. Sensitivity to a BET inhibitor, OTX-015, was assessed via dose–response assays. In vivo tumorigenicity was evaluated using subcutaneous xenografts in nude mice.

Results

MDA-NUT87 and MDA-NUT88 maintained stable morphology and harbored the characteristic t(15;19) translocation and BRD4::NUTM1 (exon 11: exon 2) fusion. The cells expressed nuclear NUT protein and responded to OTX-015 with IC₅₀ values in the low nanomolar range. Tumorigenicity was observed in vivo, albeit with modest efficiency, suggesting a contributing role of the tumor microenvironment in disease progression.

Conclusions

MDA-NUT87 and MDA-NUT88 are the first stable human sinonasal NUT carcinoma cell lines established from the primary tumor site. They preserve the hallmark genetic and phenotypic characteristics of NUT carcinoma and show sensitivity to BET inhibition. These models represent valuable tools for mechanistic studies and high-throughput drug screening in sinonasal NUT carcinoma.

目的：NUT癌是一种罕见的侵袭性恶性肿瘤，由NUTM1基因重排定义，没有标准的治疗方法和有限的临床前模型，特别是发生在鼻窦的肿瘤。我们的目的是建立和表征来自原发疾病部位的新型、稳定的鼻窦NUT癌细胞系，以促进治疗发展。实验设计：培养1例鼻窦NUT癌患者肿瘤标本，建立MDA-NUT87和MDA-NUT88两个细胞系。细胞遗传学分析、免疫组织化学、RT-PCR和Sanger测序证实了BRD4::NUTM1融合的存在。通过剂量-反应试验评估对BET抑制剂OTX-015的敏感性。用裸鼠皮下异种移植物评估体内致瘤性。结果：MDA-NUT87和MDA-NUT88形态保持稳定，具有t（15;19）易位和BRD4::NUTM1（外显子11：外显子2）融合的特征。细胞表达核NUT蛋白，对OTX-015有反应，IC50值在低纳摩尔范围内。在体内观察到致瘤性，尽管效率不高，但表明肿瘤微环境在疾病进展中起着重要作用。结论：MDA-NUT87和MDA-NUT88是第一个从原发肿瘤部位建立的稳定的人鼻窦NUT癌细胞系。它们保留了NUT癌的标志性遗传和表型特征，并表现出对BET抑制的敏感性。这些模型为鼻窦NUT癌的机制研究和高通量药物筛选提供了有价值的工具。

{"title":"Establishment of novel stable human sinonasal NUT carcinoma cell lines","authors":"Yoko Takahashi , Diana Bell , Arnoldo Corona , Shirely Y Su , Renata Ferrarotto , Brandon Gunn , Franco DeMonte , Shaan Raza , Ehab Y Hanna","doi":"10.1016/j.oraloncology.2025.107828","DOIUrl":"10.1016/j.oraloncology.2025.107828","url":null,"abstract":"<div><h3>Purpose</h3><div>NUT carcinoma is a rare and aggressive malignancy defined by <em>NUTM1</em> gene rearrangements, with no standard treatment approaches and limited preclinical models, especially for tumors arising in the sinonasal tract. We aimed to establish and characterize novel, stable sinonasal NUT carcinoma cell lines derived from the primary disease site to contribute to therapeutic development.</div></div><div><h3>Experimental design</h3><div>Tumor specimens from a sinonasal NUT carcinoma patient were cultured to establish two cell lines, MDA-NUT87 and MDA-NUT88. Cytogenetic analysis, immunohistochemistry, RT-PCR, and Sanger sequencing confirmed the presence of the <em>BRD4::NUTM1</em> fusion. Sensitivity to a BET inhibitor, OTX-015, was assessed via dose–response assays. In vivo tumorigenicity was evaluated using subcutaneous xenografts in nude mice.</div></div><div><h3>Results</h3><div>MDA-NUT87 and MDA-NUT88 maintained stable morphology and harbored the characteristic t(15;19) translocation and <em>BRD4::NUTM1</em> (exon 11: exon 2) fusion. The cells expressed nuclear NUT protein and responded to OTX-015 with IC<sub>50</sub> values in the low nanomolar range. Tumorigenicity was observed in vivo, albeit with modest efficiency, suggesting a contributing role of the tumor microenvironment in disease progression.</div></div><div><h3>Conclusions</h3><div>MDA-NUT87 and MDA-NUT88 are the first stable human sinonasal NUT carcinoma cell lines established from the primary tumor site. They preserve the hallmark genetic and phenotypic characteristics of NUT carcinoma and show sensitivity to BET inhibition. These models represent valuable tools for mechanistic studies and high-throughput drug screening in sinonasal NUT carcinoma.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"173 ","pages":"Article 107828"},"PeriodicalIF":3.9,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Oral oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀